









Markets
/
Stocks
/
nasdaq-ardx
/

Ardelyx Inc

ARDX

7.320USD

+0.320+4.57%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

1.78BMarket Cap

LossP/E TTM



Ardelyx Inc

7.320

+0.320+4.57%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Ardelyx Inc

Currency: USD Updated: 2026-02-06

Key Insights

Ardelyx Inc's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 30 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Strong Buy, with the highest price target at 14.61.In the medium term, the stock price is expected to trend up.Despite a weak stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Ardelyx Inc's Score

Industry at a Glance

Industry Ranking

30 / 392

Overall Ranking

126 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Negative

Ardelyx Inc Highlights

StrengthsRisks

Ardelyx, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing first-in-class medicines. The Company has two commercial products approved in the United States: IBSRELA (tenapanor) and XPHOZAH (tenapanor). IBSRELA is a first-in-class NHE3 inhibitor approved by the United States FDA for the treatment of irritable bowel syndrome with constipation in adults. XPHOZAH is a first-in-class phosphate absorption inhibitor approved in the United States to reduce serum phosphorus in adults with chronic kidney disease (CKD) on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy. It has agreements for the development and commercialization of tenapanor outside of the United States. Kyowa Kirin commercializes PHOZEVEL (tenapanor) for hyperphosphatemia in Japan. A New Drug Application for tenapanor for hyperphosphatemia has been approved in China with Fosun Pharma.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 539.62% year-on-year.

Undervalued

The company’s latest PE is -31.22, at a low 3-year percentile range.

Institutional Buying

The latest institutional holdings are 163.04M shares, increasing 0.08% quarter-over-quarter.

Held by Invesco

Star Investor Invesco holds 132.67K shares of this stock.

Analyst Rating

Based on 12 analysts

Strong Buy

Current Rating

14.609

Target Price

+108.70%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Ardelyx Inc is 7.77, ranking 82 out of 392 in the Biotechnology & Medical Research industry. Its financial status is weak, and its operating efficiency is high. Its latest quarterly revenue reached 110.33M, representing a year-over-year increase of 12.30%, while its net profit experienced a year-over-year increase of 19.78%.

Score

Industry at a Glance

Previous score

7.77

Change



Financials

5.22

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

6.56

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

9.55

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.51

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Ardelyx Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Ardelyx Inc is 7.93, ranking 75 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -31.22, which is -79.73% below the recent high of -6.33 and -212.55% above the recent low of -97.58.

Score

Industry at a Glance

Previous score

7.93

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 30/392

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of Ardelyx Inc is 9.33, ranking 5 out of 392 in the Biotechnology & Medical Research industry. The average price target is 11.00, with a high of 16.00 and a low of 8.00.

Score

Industry at a Glance

Previous score

9.33

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 12 analysts

Strong Buy

Current Rating

14.609

Target Price

+97.96%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

542

Total

Median

Average

Company name

Ratings

Analysts

Ardelyx Inc

ARDX

CRISPR Therapeutics AG

CRSP

argenx SE

ARGX

IQVIA Holdings Inc

IQV

Intellia Therapeutics Inc

NTLA

Beigene Ltd

ONC

...

109

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of Ardelyx Inc is 7.19, ranking 93 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 8.24 and the support level at 6.57, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.32

Change

-0.13

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(3)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.228

Neutral

RSI(14)

52.433

Neutral

STOCH(KDJ)(9,3,3)

22.964

Neutral

ATR(14)

0.436

Low Volatility

CCI(14)

-146.593

Sell

Williams %R

69.231

Sell

TRIX(12,20)

0.825

Sell

StochRSI(14)

34.698

Buy

Moving Average

Sell(3)

Neutral(0)

Buy(3)

Indicators

Value

Direction

MA5

7.446

Sell

MA10

7.632

Sell

MA20

7.529

Sell

MA50

6.546

Buy

MA100

6.041

Buy

MA200

5.361

Buy

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Ardelyx Inc is 7.00, ranking 86 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 76.72%, representing a quarter-over-quarter decrease of 4.40%. The largest institutional shareholder is The Vanguard, holding a total of 18.92M shares, representing 7.79% of shares outstanding, with 24.71% increase in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

The Vanguard Group, Inc.

Star Investors

18.31M

+14.63%

BlackRock Institutional Trust Company, N.A.

16.60M

+1.27%

Janus Henderson Investors

13.82M

-8.19%

Millennium Management LLC

7.64M

-34.48%

Nomura Investment Management Business Trust

10.46M

-8.75%

State Street Investment Management (US)

9.72M

-1.25%

Marshall Wace LLP

8.94M

-20.51%

Geode Capital Management, L.L.C.

5.76M

+1.60%

Nuveen LLC

5.05M

+45.55%

Two Sigma Investments, LP

4.11M

+26.01%

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Ardelyx Inc is 5.22, ranking 52 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is 0.60. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.